Because of the recent FDA approval, this unbranded, case based discussion will highlight PD-L1 testing in metastatic Triple Negative Breast Cancer along with the 2018 ASCO/CAP Her2 breast cancer testing guideline recommendations. Discussion topics will include:
- Biological implications of PD-L1 expression in cancer
- Describe testing algorithm and sample preparation in TNBC
- Practical implications of the 2018 update to the ASCO/CAP guidelines
- Importance of multidisciplinary collaboration to enhance quality testing
